AU2018313259B2 - solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione - Google Patents

solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione Download PDF

Info

Publication number
AU2018313259B2
AU2018313259B2 AU2018313259A AU2018313259A AU2018313259B2 AU 2018313259 B2 AU2018313259 B2 AU 2018313259B2 AU 2018313259 A AU2018313259 A AU 2018313259A AU 2018313259 A AU2018313259 A AU 2018313259A AU 2018313259 B2 AU2018313259 B2 AU 2018313259B2
Authority
AU
Australia
Prior art keywords
ing
solid form
degrees
solvate
theta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018313259A
Other languages
English (en)
Other versions
AU2018313259A1 (en
Inventor
Yamin ZHANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actuate Therapeutics Inc
Original Assignee
Actuate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63405430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2018313259(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actuate Therapeutics Inc filed Critical Actuate Therapeutics Inc
Publication of AU2018313259A1 publication Critical patent/AU2018313259A1/en
Application granted granted Critical
Publication of AU2018313259B2 publication Critical patent/AU2018313259B2/en
Priority to AU2023201059A priority Critical patent/AU2023201059B2/en
Priority to AU2025202936A priority patent/AU2025202936A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
AU2018313259A 2017-08-11 2018-08-10 solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione Active AU2018313259B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2023201059A AU2023201059B2 (en) 2017-08-11 2023-02-23 Solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
AU2025202936A AU2025202936A1 (en) 2017-08-11 2025-04-28 Solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762544277P 2017-08-11 2017-08-11
US62/544,277 2017-08-11
PCT/US2018/046203 WO2019032958A1 (en) 2017-08-11 2018-08-10 SOLID FORMS OF 3- (5-FLUOROBENZOFURAN-3-YL) -4- (5-METHYL-5H [1,3] DIOXOLO [4,5-F] INDOL-7-YL) PYRROLE-2,5-DIONE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023201059A Division AU2023201059B2 (en) 2017-08-11 2023-02-23 Solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione

Publications (2)

Publication Number Publication Date
AU2018313259A1 AU2018313259A1 (en) 2020-02-27
AU2018313259B2 true AU2018313259B2 (en) 2022-11-24

Family

ID=63405430

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2018313259A Active AU2018313259B2 (en) 2017-08-11 2018-08-10 solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
AU2023201059A Active AU2023201059B2 (en) 2017-08-11 2023-02-23 Solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
AU2025202936A Pending AU2025202936A1 (en) 2017-08-11 2025-04-28 Solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2023201059A Active AU2023201059B2 (en) 2017-08-11 2023-02-23 Solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
AU2025202936A Pending AU2025202936A1 (en) 2017-08-11 2025-04-28 Solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione

Country Status (16)

Country Link
US (3) US11136334B2 (https=)
EP (1) EP3665176B1 (https=)
JP (3) JP7424639B2 (https=)
KR (3) KR102700883B1 (https=)
CN (2) CN117362305A (https=)
AU (3) AU2018313259B2 (https=)
BR (1) BR112020002892A2 (https=)
CA (1) CA3072240A1 (https=)
DK (1) DK3665176T3 (https=)
ES (1) ES2974328T3 (https=)
FI (1) FI3665176T3 (https=)
IL (2) IL272556B2 (https=)
MX (3) MX2020001547A (https=)
PL (1) PL3665176T3 (https=)
PT (1) PT3665176T (https=)
WO (1) WO2019032958A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3697794T3 (pl) 2017-10-16 2026-04-07 Actuate Therapeutics Inc. Stałe postacie 3-(5-fluorobenzofuran-3-ylo)-4-(5-metylo-5h-[1,3]dioksolo[4,5-f]indol-7-ilo)pirolo-2,5-dionu
WO2019222483A1 (en) * 2018-05-17 2019-11-21 Board Of Regents, The University Of Texas System Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form beta inhibitors
US20250325517A1 (en) * 2022-06-27 2025-10-23 Actuate Therapeutics, Inc. Oral dosage forms of elraglusib

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008077138A1 (en) * 2006-12-19 2008-06-26 The Board Of Trustees Of The University Of Illinois 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12012501293A1 (en) 2009-12-23 2013-01-07 Arqule Inc Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008077138A1 (en) * 2006-12-19 2008-06-26 The Board Of Trustees Of The University Of Illinois 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
IRINA N. GAISINA ET AL, "From a Natural Product Lead to the Identification of Potent and Selective Benzofuran-3-yl-(indol-3-yl)maleimides as GSK 3[beta] Inhibitors .. ", J Med Chem, 2009, vol. 52, no. 7, pages 1853 - 1863 *

Also Published As

Publication number Publication date
CN117362305A (zh) 2024-01-09
MX2020001547A (es) 2020-08-03
ES2974328T3 (es) 2024-06-26
PL3665176T3 (pl) 2024-06-17
JP7778750B2 (ja) 2025-12-02
IL313800A (en) 2024-08-01
BR112020002892A2 (pt) 2020-08-04
KR102700883B1 (ko) 2024-09-02
JP2023156372A (ja) 2023-10-24
KR20240063198A (ko) 2024-05-09
KR20250070131A (ko) 2025-05-20
AU2025202936A1 (en) 2025-05-15
CN111247153B (zh) 2024-04-02
US20220009939A1 (en) 2022-01-13
MX2024003249A (es) 2024-04-04
IL272556B1 (en) 2024-09-01
AU2023201059A1 (en) 2023-03-23
EP3665176A1 (en) 2020-06-17
DK3665176T3 (da) 2024-03-25
JP2020530497A (ja) 2020-10-22
US20250115616A1 (en) 2025-04-10
US20200223861A1 (en) 2020-07-16
WO2019032958A1 (en) 2019-02-14
US11136334B2 (en) 2021-10-05
CA3072240A1 (en) 2019-02-14
AU2023201059B2 (en) 2025-04-03
PT3665176T (pt) 2024-03-13
AU2018313259A1 (en) 2020-02-27
EP3665176B1 (en) 2024-01-24
US12145943B2 (en) 2024-11-19
KR20200040799A (ko) 2020-04-20
FI3665176T3 (fi) 2024-03-20
IL272556A (en) 2020-03-31
MX2023005875A (es) 2023-06-05
CN111247153A (zh) 2020-06-05
JP7424639B2 (ja) 2024-01-30
JP2026012715A (ja) 2026-01-27
IL272556B2 (en) 2025-01-01

Similar Documents

Publication Publication Date Title
AU2023201059B2 (en) Solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
US20250115615A1 (en) Solid Forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
BR112020007538B1 (pt) Forma sólida, processo para preparar a forma sólida, composição farmacêutica, processo para preparar a composição farmacêutica e uso da forma sólida
BR122025019554A2 (pt) Forma sólida de 3-(5-flúor-benzofuran-3-il)-4-(5-metil-5h-[1,3]dioxolo[4,5- f]indol-7-il)pirrol-2,5-diona, seus usos, composição farmacêutica e processo para preparar a mesma

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)